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L ong-term survival after cancer of the esophagus orthe gastroesophageal junction remains poor despite
significant advances in surgical techniques and periop-
erative management.1-4 Even after apparently curative
surgery, the overall 5-year survival is only 30% to 50%.
In approximately one third of the patients, the recur-
rence is located in the operative field. The lesions are
usually seen in regional lymph nodes or as a mass orig-
inating in the mediastinum and infiltrating the gastric
pull-up from outside. The majority of the recurrences,
however, are distant metastases, indicating the systemic
Objective: To study the utility of whole-body positron emission tomography
with 18F-fluoro-deoxy-D-glucose (FDG-PET) for the evaluation of recur-
rence after curative resection of cancer of the esophagus or gastroesophageal
junction.
Methods: Forty-one patients with a clinical or radiologic suspicion of recur-
rent disease underwent conventional diagnostic work-up, including a spiral
computed tomographic scan, an endoscopic ultrasound, and a dedicated
whole-body FDG-PET. PET lesions were classified as equivocal or suspi-
cious recurrence. The conventional diagnostic work-up and PET findings
were correlated with pathology or with radiologic and clinical follow-up.
Equivocal lesions were classified as positive.
Results: Forty recurrences were found in 33 patients. The lesions were peri-
anastomotic (n = 9), regional (n = 12), and at distant sites (n = 19). For the
diagnosis of a perianastomotic recurrence, the sensitivity, specificity, and
accuracy of FDG-PET were 100%, 57%, and 74%, versus 100%, 93%, and
96% for conventional diagnostic work-up, respectively (P = not signifi-
cant). False-positive PET lesions were found in patients with a progressive
anastomotic stenosis requiring repetitive endoscopic dilatation. For the
diagnosis of regional and distant recurrences, the sensitivity, specificity,
and accuracy of PET were 94%, 82%, and 87%, versus 81% (P = not sig-
nificant), 82% (P = not significant), and 81% (P = .0771) for conventional
diagnostic work-up. All false-positive PET lesions (n = 4) had been report-
ed as equivocal. On a patient base, PET provided additional information in
11 of 41 (27%) patients. A major impact on diagnosis was found in 5
patients with equivocal or negative findings on complete diagnostic work-
up in whom PET provided a true-positive diagnosis. In 5 other patients the
diagnosis was staged upward from localized to extended recurrent disease,
and in 1 patient with an equivocal complete diagnostic work-up, PET cor-
rectly excluded malignancy. 
Conclusion: FDG-PET allows a highly sensitive diagnosis and accurate
whole-body staging of symptomatic recurrent esophageal cancer. Further
studies in asymptomatic patients are needed to assess the potential benefit on
survival. (J Thorac Cardiovasc Surg 2000;120:1085-92)
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character of the disease.5-7 Two thirds of patients have
a recurrence within 1 year and nearly all within 2 years
after the primary operation.8 Nevertheless, most centers
do not actively search for tumor recurrence in asymp-
tomatic patients because the survival benefit of such an
approach remains controversial. Some reports, howev-
er, suggested that early detection of recurrent disease is
desirable because aggressive treatment may result in
prolonged tumor-free survival or occasional cure.9 The
conventional diagnostic work-up (CDW) currently
available for the postoperative diagnosis and staging of
recurrent disease includes endoscopy, transesophageal
endoscopic ultrasound (EUS), and computed tomogra-
phy (CT) of the chest and abdomen. A fundamental
limitation of these techniques is that they depend
entirely on anatomic and/or structural criteria for diag-
nosis. Therefore, their specificity is hampered by ther-
apy-induced changes of the tissue characteristics at the
operative site.10 Moreover, strictures at the esopha-
gogastric anastomosis often preclude full passage of
the endoscope, resulting in incomplete diagnosis in one
third of the patients.11
Recent reports indicated a role for whole-body
positron emission tomography (PET) using the radiola-
beled glucose analog 18F-fluoro-deoxy-D-glucose
(FDG) for preoperative staging of cancer of the esoph-
agus and gastroesophageal junction.12-16 PET uses a
metabolic approach to diagnosis. The depiction of neo-
plastic foci by FDG-PET relies on the increased accu-
mulation of the radioactive tracer in malignant tissues,
which is believed to be the result of an increased
expression of glucose transport enzymes in the tumoral
cell membrane, together with an increased activity of
the enzymes of the first steps of the glycolytic path-
way.17,18 Early reports suggested that PET had a signif-
icant advantage over the conventional methods (spiral
CT and EUS) for the detection of distant metastases
and thus for the diagnosis of nonresectable disease. For
assessing locoregional lymph node metastases, PET
was as accurate as CDW and more specific. No data are
yet available about the potential of PET used in the fol-
low-up of patients after resection of esophageal cancer.
The purpose of this study was to investigate the utility
of FDG-PET for the diagnosis and staging of disease in
patients in whom recurrent esophageal cancer was sus-
pected.
Methods
Patients. The database of the PET department was
searched for all in-house patients who underwent a whole-
body FDG-PET scan for clinical and/or radiologic suspicion
of recurrent esophageal cancer during the period January
1998 until June 1999. Only patients who had undergone an
esophagectomy with curative intent were selected. 
CDW. In all patients routine CDW was performed in house
according to high-standard practice, including spiral CT of
chest and abdomen (n = 39), transesophageal EUS (n = 13),
and endoscopy (n = 18). In some patients, other sign- or
symptom-directed dedicated techniques such as bone scan or
spiral CT of the neck were also performed. In 11 patients full
passage of the echoendoscope was impossible, precluding
accurate EUS diagnosis. These patients underwent an
endoscopy. The lesions reported by CDW were classified as
equivocal or suspicious for recurrence.
FDG-PET imaging. The PET imaging was performed
with a CTI-Siemens 931 or HR+ scanner (CTI, Inc,
Knoxville, Tenn) with an axial field of view of 10.1 cm and
15 cm, respectively, and a spatial resolution of 8 and 6 mm,
respectively. All patients fasted for 6 hours before the tracer
administration. Sixty minutes after the intravenous injection
of a 6.5 MBq/kg dose of 18F-FDG (to a maximum of 555
MBq), a whole-body emission scan was performed. The raw
imaging data were reconstructed in a 128 × 128 matrix with
the use of an iterative reconstruction algorithm. 
For the purpose of this study, all PET images were
reviewed by two experienced nuclear medicine physicians
(A.M. and J.P.C.). At the time of image review, these
observers were fully aware of the history of the patients,
the type of esophagectomy performed, the location of the
esophagogastric anastomosis, and the patients’ symptoms.
However, the observers were completely blinded to the
results of the concurrent CDW and to the follow-up data. In
case of diagnostic discordances between the observers, a
consensus diagnosis was generated. The PET lesions were
classified as equivocal or suspicious for recurrence.
Data analysis. The results of CDW and of FDG-PET were
compared with a gold standard that consisted of histologic
findings or of clinical and radiologic follow-up. A follow-up
of at least 6 months was needed for a definitive negative diag-
nosis.
For the region-based analysis, recurrences were assigned to
3 regions: (1) the perianastomotic area, located around the
esophagogastric anastomosis; (2) the regional area, corre-
sponding to the operative field of the primary esophagecto-
my, including the mediastinum and upper abdominal com-
partment, and also the cervical area when a 3-field
lymphadenectomy had been performed; and (3) distant areas,
if the lesions were located in organs or lymph nodes outside
the initial operative field. 
The calculations of the accuracies of CDW and PET took
into account only those regions for which a gold standard was
available. For these calculations, CDW and PET lesions that
were classified as equivocal were considered as positive.
The sensitivity, specificity, and accuracy of CDW and
FDG-PET were calculated by the standard definitions.
McNemar χ2 testing was used to compare the sensitivity,
specificity, and accuracy of PET and CDW as dependent
samples by means of 2 × 2 tables.
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Results
Patients. Forty-one patients were included for analy-
sis. Table I lists the patients’ demographics, primary
esophageal tumor type and location, type of operation
that was performed on the primary tumor, pathologic
TNM staging (pTNM), and the location of the esopha-
gogastric anastomosis.
The suspicion of tumor recurrence was based on the
presence of dysphagia (n = 8), hoarseness (n = 8), pain
(n = 9), deterioration of the general condition (n = 11),
or abnormalities detected during routine clinical or
radiologic examinations (n = 5). The mean time
elapsed between the date of the primary operation and
the date of the PET scan was 506 days (range 54-2151
days).
The gold standard established cancer recurrence in
33 of 41 (80%) patients. Table II shows the regional
distribution of the recurrences and the gold standard
used to define the true lesion status. The sensitivity,
specificity, and accuracy of CDW and FDG-PET for
the diagnosis of perianastomotic recurrence, locore-
gional recurrence, and distant metastasis are shown in
Table III. Overall, sensitivity of FDG-PET was higher
than that of CDW (95% vs 85%; P = not significant
[NS]). The specificity, on the other hand, was lower
(72% vs 86%; P = NS). This resulted in a similar over-
all accuracy of the two diagnostic approaches (84% vs
86% for PET and CDW, respectively). 
Perianastomotic recurrence. The gold standard
established perianastomotic recurrent disease in 9 of 41
(22%) patients. Both CDW and PET detected all the
lesions, resulting in a 100% sensitivity for both
approaches. A definite negative diagnosis was made in
14 patients. This patient subset was used for calculation
of the specificity. The specificity of PET was lower
than that of CDW (57% vs 93%, respectively) due to
false-positive PET lesions found in 6 of 14 patients.
These lesions were classified as suspicious in 3 patients
and as equivocal in 3 other patients. A review of the
records of these patients revealed that the former 3
patients had undergone an endoscopic dilation treat-
ment for a benign stricture 7, 14, and 55 days, respec-
tively, before the PET scan was performed. In 2 of
these patients the dilatation was performed less than a
week before the PET scan and in the other patient, 55
days before the PET scan. An illustrative example of a
PET lesion falsely classified as suspicious for recur-
rence at the perianastomotic site is shown in Fig 1. The
3 other patients had only moderately intense lesions,
and because of this their status was classified as equiv-
ocal. In 2 of these patients endoscopy revealed a stric-
ture of the anastomosis, without a recent therapeutic
dilation. In the third patient the time interval between
the primary operation and the PET scan was only 54
days. The lesion probably reflected postoperative
inflammatory healing processes.
Regional recurrence. The gold standard indicated a
regional recurrence in 12 patients and the absence of
recurrent disease in 12 patients. CDW had a lower sen-
sitivity than PET (83% and 92%, respectively) and a
higher specificity (92% and 83%, respectively), result-
ing in a minimally different accuracy (83% and 88%,
respectively). One false-negative PET was found in a
patient with a biopsy proven recurrent tumor of more
than 2 cm in diameter located in the upper retroperi-
Table I. Patients’ characteristics
Characteristics No.
Demographics
Mean age (standard deviation) 62 (9)
Male/female 36/5
Primary esophageal tumor
Adenocarcinoma/spinocellular carcinoma 27/14
Location
Proximal 3
Middle 8
Distal 12
GE junction 18
Primary curative surgery
Partial esophagogastrectomy 
With cervical anastomosis 35
With intrathoracic anastomosis 5
Endoscopic mucosectomy 1
pTNM
Stage 1 6
Stage 2 5
Stage 3 14
Stage 4 16 
Invaded surgical resection margins 5
R0/R1/R2 resection 37/3/2
Table II. Distribution of the recurrences and the
methods used to define the true lesion status (gold
standard) 
True lesion status defined by:
No. of Follow-up 
recurrences Histology (mean duration)*
Anastomosis 9 8 1 (102 days)
Regional 12 7 5 (122 days)
Distant 19 8 11 (105 days)
Total 40 23 (58%) 17 (42%)
*The mean duration represents the mean time elapsed between the date of the
PET and the clinical and/or radiographic confirmation of the true-lesion sta-
tus.
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toneal area. A close review of the PET scan with visu-
al registration of PET and CT images revealed only a
faint tracer uptake at the site of the suspicious mass.
The resected primary tumor was a pT3 N2 M0 adeno-
carcinoma of the gastroesophageal junction with a
marked signet cell differentiation.
False-positive PET scans were found in 2 patients:
both lesions were only moderately intense and were
considered as equivocal. The first lesion was located
in the anterior mediastinum and was not confirmed
by follow-up CT performed 9 months later. The latter
lesion was located in the right lung hilus. Histologic
Table III.  Regional based analysis
Gold standard CDW FDG-PET
Region of recurrence + – Sensitivity Specificity Accuracy Sensitivity Specificity Accuracy
Anastomosis 9 14 9/9 13/14 22/23 9/9 8/14 17/23
100% 93% 96% 100% 57% 74%
Regional
12 12 10/12 11/12 21/24 11/12 10/12 21/24
83% 92% 88% 92% 83% 88%
Distant
19 10 15/19 7/10 22/29 18/19 8/10 26/29
79% 70% 76% 95% 80% 90%
All 40 36 34/40 31/36 65/76 38/40 26/36 64/76
85% 86% 86% 95% 72% 84%
Fig 1. Example of a false-positive FDG-PET finding at the anastomosis. This patient had dysphagia 1 year after a
subtotal esophagogastrectomy and cervical esophagogastrostomy. Endoscopy indicated a benign intrinsic stenosis
of the esophagogastric anastomosis and an endoscopic dilatation was succesfully performed. Two weeks later the
PET scan showed an intense focal hot spot in the upper mediastinum. Seven months’ clinical and radiologic fol-
low-up did not show any signs of recurrent disease.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 120, Number 6
Flamen et al 1089
examination of the hilar lymph nodes indicated
inflammation.
Distant metastases. The gold standard indicated dis-
tant metastatic disease in 19 patients: CDW detected
lesions in 15 (sensitivity 79%) and FDG-PET in 18
(sensitivity 95%) of these. The PET scan was false-
negative in only 1 patient, in whom diffuse miliary
peritoneal metastases were found during a diagnostic
laparoscopy. Conventional imaging was also false-neg-
ative in this patient.
False-positive PET images were found in 2 patients.
One had a moderately intense FDG uptake in a spinal
location, which was considered as equivocal. Other
investigations and a disease-free follow-up of more
than 1 year did not confirm the diagnosis of a bone
metastasis. Another patient had a moderately intense
lesion, also considered as equivocal, located in the
periphery of the left lung. The CT of that region
showed a thickened pleura and some parenchymatous
sequelae of infection.
Regional and distant recurrences. For the diagno-
sis of a nonperianastomotic recurrence, that is, region-
al and distant, the sensitivity, specificity, and accuracy
of PET were 94%, 82%, and 87% versus 81% (P =
NS), 82% (P = NS), and 81% (P = .0771) for CDW.
Five lesions were classified as equivocal by PET: 2
regional and 3 distant lesions. The gold standard, avail-
able in 4 of them, indicated the absence of recurrent
tumor. The 2 regional lesions were located in the lung
hilus and in the anterior mediastinum. The 2 distant
lesions were located in the lungs and in the bone. After
close multidisciplinary correlation with clinical and/or
radiographic findings, these lesions were considered as
probably inflammatory and, therefore, did not induce
Fig 2. Example of a whole-body FDG-PET in a patient having hoarseness 6 months after a subtotal esophagogas-
trectomy and cervical esophagogastrostomy for a spinocellular epithelioma staged pT3 N1 Mb. CDW, including
endoscopy and CT, did not demonstrate recurrent tumor. FDG-PET showed multiple sites of tumor recurrences in
the upper mediastinum (A), upper abdominal retroperitoneum (B), and in the perigastric area (C). All these lesions
were confirmed by radiologic follow-up 3 months later.
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any diagnostic or therapeutic change. Importantly, none
of the equivocal PET lesions proved to be malignant.
Patient-based analysis.  On a patient basis, PET
and CDW were completely concordant in 25 of 41
(61%) patients. Of the 16 patients with discordant
PET findings, PET improved the diagnosis in 11
patients. According to the degree of potential clinical
impact in these patients, the added value of PET was
classified as major when a potential treatment could
have been installed, withheld, or changed as a conse-
quence of the PET findings; the value was classified
as minor in case PET did not significantly change the
management of the patient. A major contribution of
PET was found in 5 of 41 (12%) patients in whom it
correctly diagnosed recurrent disease not detected by
CDW. Fig 2 shows the FDG-PET images of such a
patient. In 6 other patients, contribution of PET to the
correct diagnosis was only minor: in 5 of these
patients PET detected more lesions than CDW, and in
another patient with equivocal CDW findings FDG-
PET correctly excluded a bone metastasis as the cause
of a dorsal vertebral collapse.
On the other hand, PET had a potentially negative
impact on diagnosis in 5 patients. PET falsely under-
staged the disease in 1 patient because of a false-nega-
tive finding, and it falsely overstaged the disease in 4
patients due to false-positive findings. 
Discussion 
Recently published studies investigated the useful-
ness of FDG-PET for primary staging of esophageal
cancer. The diagnostic superiority of metabolism-based
methods such as FDG-PET should be most pronounced
in those circumstances in which nonspecific sequelae
of surgery, radiotherapy, or chemotherapy render the
conventional, anatomy-based modalities less accurate.
This is substantiated by several reports on the success-
ful use of FDG-PET for the metabolic imaging of
perirectal masses often occurring after surgery of rectal
adenocarcinomas and in the surveillance of patients
operated on for head and neck carcinoma.19,20 The cur-
rent study is the first that specifically focused on the
utility of FDG-PET imaging for the diagnosis and stag-
ing of recurrent esophageal cancer. Our preliminary
results suggest that FDG-PET provides a highly sensi-
tive diagnosis (overall sensitivity 95%) of recurrent dis-
ease, both locoregionally and at distant sites. However,
in contrast to the reported findings in colorectal and
head and neck cancer,19,20 PET does not seem to
enhance the diagnostic accuracy for locoregional recur-
rences. 
We believe that the inclusion criteria of this study led
to an underestimation of the additional value of PET.
Only patients with a clinical or radiologic suggestion of
recurrence were referred for a PET scan. The pre-test
probability of finding recurrent tumor in these patients
is very high. Indeed, 80% of the included patients had
recurrent disease, often in advanced stages, leaving
only the small fraction of CDW-negative patients to test
the additional value of PET. Nevertheless, the very high
sensitivity of PET supports the hypothesis that PET
could allow an earlier and presumably preclinical diag-
nosis of esophageal cancer recurrence. It certainly jus-
tifies further prospective studies in this respect. Such
studies have been reported using CT or EUS as sur-
veillance tools in the year after the primary operation.
In a prospective follow-up of patients with routine CT,
Barbier and associates11 showed that the symptom-free
interval exeeded the tumor-free interval by 4 months.
However, the earlier detection of asymptomatic recur-
rences had no impact on outcome. More recently, EUS
was tested in a similar setting. It was found that EUS
performed routinely in the postoperative follow-up
detected recurrences in 67% of the asymptomatic
patients, on average 3 months before their condition
became symptomatic.21 An important limitation of
EUS is that a benign anastomotic stricture precluding
passage of an endoscope after cervical esophagogas-
trostomy will develop in approximately 30% of
patients.22
Whether earlier diagnosis of recurrent esophageal
cancer would improve patient survival has not been
reported yet. The possibility of a survival benefit, how-
ever, can be deduced indirectly from results obtained in
a study with primary chemotherapy in asymptomatic
patients with advanced colorectal cancer, indicating a
survival benefit of 6 months.23 The available therapeu-
tic modalities in recurrent esophageal cancer are radi-
cal reresection, palliative resection and bypass, laser
thermocoagulation, stenting, chemotherapy, brachy-
therapy, and radiotherapy, alone or in combination. The
choice of a specific therapeutic modality depends on
the extent of the recurrence. Our study results indicate
that FDG-PET at that point could contribute to patient
care because it provides, in one imaging session cover-
ing the whole body, an accurate assessment of the
extent of disease.
A noteworthy finding in the current study is the high
incidence of false-positive PET findings at the peri-
anastomotic region. By reviewing the patients’ records,
we found that the patients with intense false-positive
FDG uptake all had undergone an endoscopic dilation
of a benign anastomotic stricture as long as 55 days
before the PET scan. Probably the dilation induced a
trauma resulting in an inflammatory reaction. False-
positive FDG uptake at inflammatory lesions is widely
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known and remains a major problem in the diagnosis of
oncologic patients.24 Three other patients had only
moderate uptake at the anastomosis. In 2 of these
patients, a nontumoral stricture was found endoscopi-
cally. However, a dilatation had not been performed,
and the accumulation of FDG may have been due to
proliferating fibroblastic and/or granulomatous tissue
at the anastomosis. The other patient underwent scan-
ning less than 2 months after the primary operation.
The FDG uptake in this patient probably reflected a
normal inflammatory healing process. This means that
interpretation of the PET scan at the anastomotic site
needs careful correlation with clinical data before a
positive diagnosis can be made. The specificity of PET
at the regional and distant sites is clearly higher
although certainly not perfect. Importantly, all 4 false-
positive PET lesions, falsely overstaging the disease in
4 patients, were considered as equivocal by the blinded
PET reviewer. The decision to classify these equivocal
studies as positive was based on the fact that in other
types of tumors these lesions sometimes do indicate the
presence of a limited load of neoplastic cells. However,
in our experience the clinical impact of these equivocal
PET lesions is often relatively limited. Multi-
disciplinary confrontation of the PET findings with
clinical data, together with close correlation of PET
and CT images, which was not done in this study, often
neutralizes the potential negative impact of these
equivocal lesions. Indeed, in our study, the 4 lesions
reported as equivocal on PET did not induce any
change of patient management because these lesions
lacked any clinical or radiologic correlation. The
impact of false-positivity of PET would be more pro-
nounced if the technique were used as an early diag-
nostic maneuver. In that case correlative CT imaging
would frequently be necessary to decide on equivocal
PET lesions.
We conclude that (1) FDG-PET allows a highly sen-
sitive diagnosis and accurate whole-body staging of
symptomatic recurrent esophageal cancer; (2) FDG-
PET is not accurate for diagnosis of perianastomotic
recurrence owing to frequent false-positive findings
based on FDG accumulation in areas of inflammation;
(3) a multidisciplinary correlative approach is essential
to reduce the potential negative impact of false-positive
PET diagnosis on patient care; (4) prospective studies
using PET in asymptomatic patients are needed to
study the potential benefit of earlier diagnosis of recur-
rent disease on patient survival and quality of life.
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